Visiongain has published a new report on Antibody Production Market Report to 2031. According to the Visiongain analysis, the global Antibody Production market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Antibody Production market is segmented by process, type & end user. By process, the market is categorized as (Upstream Processing (Bioreactors, Consumables), Downstream Processing (Chromatography Systems, Chromatography Resins), Filtration (Filtration Systems, Filtration Consumables & Accessories), By Type ( Monoclonal, Polyclonal), By End User ( Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antibody Production Companies. PLUS COVID-19 Recovery Scenarios.

Global Antibody Production Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The rising adoption of targeted immunotherapy and increasing R&D activities in pharmaceutical and biotechnological companies are factors driving the growth of antibody production market.

COVID-19 Impact on the Global Antibody Production Market
The COVID-19 pandemic has affected the global economy due to stringent government regulations around the globe. Eli Lilly's bamlanivimab is a potent, neutralizing IgG1 monoclonal antibody directed against the spike protein of SARS-CoV-2 coronavirus. However, the government-sponsored clinical trial testing of the antibody has been paused due to “potential safety concern”.

Market Driver
Rising adoption of targeted immunotherapy
The monoclonal antibodies (MAbs) are used as therapeutics in the treatment of cancer, autoimmune disorders, and inflammatory diseases. The prevalence of infectious diseases increases the demand for monoclonal antibodies around the globe. Healthcare reforms in the emerging economies and growing investment in the antibody production market will boost the market in near future.

Market Opportunity
Expiring patent of therapeutic monoclonal antibody.
A patent is considered as the determinant for innovators to pledge market exclusivity and enables to block entry of biosimilars in the market. However, the patent disputes between companies may cause uncertainty on the validity of an innovator’s patent or influence the launch of biosimilar through strategies for prolongation of exclusivity rights of the company.
In October 2018, numerous biosimilars for adalimumab entered the European market after the expiry of the basic patent, supplementary protection certificate (SPC) and a 6-month pediatric extension, which is followed by settlement agreement, includes non-exclusive license on patents for dosage regimens for rheumatoid arthritis and inflammatory bowel disease.

Increasing prevalence of` infectious diseases

The increasing incidence of infectious diseases, associated with increasing demand for protein therapeutics, boosts the antibody production market, globally. According to WHO, infectious diseases are world's biggest killer, which accounts for more than 13 million deaths per year, one in two deaths in developing countries. Almost 90.0% of deaths are caused due to handful of infectious diseases such as pneumonia, tuberculosis, and HIV. Due to approval of advanced drugs the therapeutics antibody drugs enhanced it growth to treat diseases such as cancer, autoimmune, metabolic & infectious diseases.

Competitive Landscape
GE Healthcare, Thermo Fisher Scientific, Inc., 3M, Abcam PLC, GeneTex, Inc., Sartorius AG , Merck KGaA, Pall Corporation, Sigma-Aldrich Corporation, Eppendorf AG, Cellab GmbH, Pfizer Inc. are some of the key players contributing to the growth of the global Antibody Production market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.

For instance, in November 2018, Glenmark Pharmaceuticals, announced to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. The result is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript platform. GBR 1342 is based on the company’s proprietary Bispecific Engagement by Antibodies based on the T cell receptor (BEAT)platform, which simultaneously targets CD38 and the CD3 T cell co-receptor. The company intends to file an Investigational New Drug (IND) application for GBR 1342 in solid tumors and initiate a clinical trial in 2019.

In January 2020, CytoDyn announced the filing for Breakthrough Therapy designation with the FDA, leronlimab to treat metastatic triple-negative breast cancer in patients. In February 2020, the company announced Institutional Review Board approval to initiate a Phase 2 basket trial for 22 solid tumor cancers.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.